3.19. Analysis.
Comparison 3 Any antiglucocorticoid versus placebo as adjunct to combination treatment, Outcome 19 Adverse effects: 2b. Specific ‐ extrapyramidal symptoms ‐ average endpoint scores ‐ data only for DHEA (skewed data).
| Adverse effects: 2b. Specific ‐ extrapyramidal symptoms ‐ average endpoint scores ‐ data only for DHEA (skewed data) | ||||
|---|---|---|---|---|
| Study | Intervention | Mean | SD | N |
| extrapyramidal symptoms (ESRS total, higher score = poor) | ||||
| Ritsner 2006 | DHEA | 4.0 | 6.8 | 29 |
| Ritsner 2006 | Placebo | 5.5 | 8.5 | 26 |
| Ritsner 2010 | DHEA | 2.9 | 4.8 | 13 |
| Ritsner 2010 | Placebo | 1.7 | 4.1 | 11 |
| Akathisia and tardive dyskinesia (AIMS/BARS total, higher score = poor) | ||||
| Ritsner 2006 | DHEA | 1.1 | 2.8 | 29 |
| Ritsner 2006 | Placebo | 0.8 | 2.3 | 26 |
| Ritsner 2010 | DHEA | 0.23 | 0.6 | 13 |
| Ritsner 2010 | Placebo | 0.18 | 0.4 | 11 |